Volaris September load factor rises 1.0 pp to 84.4%
Bitget2026/10/06 13:02Controladora Vuela Compañía de Aviación reported September 2026 traffic results with consolidated load factor up 1.0 pp to 84.4%. Capacity rose 1.9% to 2,814 million ASMs; traffic increased 3.1% to 2,375 million RPMs. Domestic RPMs fell 3.8% to 1,366 million; international RPMs climbed 14.2% to 1,010 million. Passenger volumes grew 4.2% to 2,475,000, driven by a 12.2% rise in international passengers to 689,000. Third-quarter capacity increased 11.1%; consolidated load factor improved 1.3 pp to 85.7%. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Controladora Vuela Compañía de Aviación SAB de CV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001292814-26-004856), on October 06, 2026, and is solely responsible for the information contained therein.
- Controladora Vuela Compañía de Aviación reported September 2026 traffic results with consolidated load factor up 1.0 pp to 84.4%.
- Capacity rose 1.9% to 2,814 million ASMs; traffic increased 3.1% to 2,375 million RPMs.
- Domestic RPMs fell 3.8% to 1,366 million; international RPMs climbed 14.2% to 1,010 million.
- Passenger volumes grew 4.2% to 2,475,000, driven by a 12.2% rise in international passengers to 689,000.
- Third-quarter capacity increased 11.1%; consolidated load factor improved 1.3 pp to 85.7%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley raises CME Group price target to $337
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories
Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.
Crypto prices
More
